Alzheimer's/Dementia Presentations
- VHS
- Department of Medicine
- Centers
- Glennan Center for Geriatrics and Gerontology
- Glennan Center Research
- Alzheimer's/Dementia Presentations
Navigating Early Stages AD Therapies: Facts You Should Know
Update on the Recent FDA-Approved Medications in Alzheimer's Disease & Next Generation Therapeutics
Preventing Dementia: Is it Possible?
Beyond Amyloid-Beta: Nutrition and Lifestyle for Dementia Prevention
Dr. Paul Aravich, neuroscientist and professor of Pathology and Anatomy, Geriatrics, and Physical Medicine and Rehabilitation discusses successful aging and preventing dementia through nutrition and lifestyle.
A Call to Action: Brain Health in the African-American Community
The Alzheimer's Association Southeastern Virginia Chapter presented A Call to Action: Brain Health in the African-American Community as part of a virtual conference focused on disparities in dementia on April 29, 2022.
"New Alzheimer's Therapeutics: What Is on the Horizon?" by Dr. Hamid Okhravi
Dr. Hamid Okhravi, Associate Professor of Geriatrics and Director of, the Memory Consultation Clinic, Glennan Center for Geriatrics and Gerontology expounds on research and clinical trial data of emerging therapeutics in Alzheimer's disease.
Learn more about Dr. Okhravi's work with the Glennan Center for Geriatrics and Gerontology.
Video courtesy of VCU Health Department of Internal Medicine, Medical Grand Rounds.
PrimeTime with Bob: Meet Dr. Hamid Okhravi, MD
Dr. Hamid Okhravi, Associate Professor of Geriatrics and Director, of Memory Consultation Clinic, Glennan Center for Geriatrics and Gerontology talks with Executive Director Bob Batcher of Primeplus Senior Centers about Alzheimer's disease, dementia, and the current clinical trial AHEAD3-45 at the Glennan Center for Geriatrics and Gerontology.
During the early stages of Alzheimer's disease, amyloid protein forms plaques in the brain. The AHEAD study is a Phase 3 clinical trial that will test whether the study drug, Lecanemab (BAN2401), reduces brain amyloid buildup in people with an increased risk of Alzheimer's disease. Study participants will be enrolled in one of two AHEAD trials based on whether they have intermediate or elevated levels of amyloid in their brains.
Learn more about the AHEAD3-45 study and how you can become involved.
Video courtesy of Primetime Senior Centers.